Sanofi takes a $260M hit to extricate itself from a disastrous alliance with Lexicon
Sanofi spent $300 million in cash to get into a $1.7 billion alliance with Lexicon on their SGLT1/2 diabetes drug sotagliflozin. And now that the drug has been spurned by the FDA after burning through a program that provided mixed late-stage data and a late shot at a last-place finish, the French pharma giant is forking over another $260 million to get out of the deal.
Sanofi’s unhappiness was already apparent when the company — now under new CEO Paul Hudson — posted a statement back in July that they were dropping the deal. But it wasn’t that simple.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.